Stuart Hogarth

Dr. Stuart Hogarth


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2008 in Annual Review of Genomics and Human Genetics
Verified
Journal Article
Closed access
SHStuart Hogarth
Stuart Hogarth
GJGail Javitt
Gail Javitt
DMDavid Melzer
David Melzer
This review surveys the developing market for direct-to-consumer (DTC) genetic tests and examines the range of companies and tests available, the regulatory landscape, the concerns raised about DTC testing, and the calls for enhanced oversight. We provide a comparative overview of the situation, particularly in the United States and Europe, by exploring the regulatory frameworks for medical devices and clinical laboratories. We also discuss a variety of other mechanisms such as general controls on advertising and consumer law mechanisms.

5 November 2013 in PLOS Biology
Verified
Journal Article
Open access
PDF file
TCTimothy Caulfield
Timothy Caulfield
JEJim Evans
Jim Evans
AMAmy McGuire
Amy McGuire
CMChristopher McCabe
Christopher McCabe
TBTania Bubela
Tania Bubela
BWBrenda Wilson
Brenda Wilson
The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.

3 July 2017 in New Genetics and Society
Verified
Journal Article
Closed access
SHStuart Hogarth
Stuart Hogarth
Drawing on the sociology of expectations and sociology of conventions, this paper explores issues of worth and value in the bioeconomy, and the promissory character of contemporary capitalism. Arguing that the literature on biocapital has paid insufficient attention to geographical differentiation in capital accumulation strategies, this paper situates the consumer genomics firm 23andme in the entrepreneurial culture of Silicon Valley. The paper suggests that in Silicon Valley the relationship between moral worth and economic value is mediated through the concept of disruptive innovation, which functions as both ideological construct and a set of commercial practices utilized by the founders of start-up firms and the venture capitalists who invest in them. Analyzing 23andme’s status as a “unicorn” firm, the paper describes how the recent increase in private investment capital in Silicon Valley has led to a new model of business development for start-ups and considers its implications for corporate governance.

1 March 2010 in Social Science & Medicine
Verified
Journal Article
Open access
PSPaula M. Saukko
Paula M. Saukko
MRMatt Reed
Matt Reed
NBNicky Britten
Nicky Britten
SHStuart Hogarth
Stuart Hogarth
Genomics researchers and policy makers have accused nutrigenetic testing companies--which provide DNA-based nutritional advice online--of misleading the public. The UK and USA regulation of the tests has hinged on whether they are classed as "medical" devices, and alternative regulatory categories for "lifestyle" and less-serious genetic tests have been proposed. This article presents the findings of a qualitative thematic analysis of the webpages of nine nutrigenetic testing companies. We argue that the companies, mirroring and negotiating the regulatory debates, were creating a new social space for products between medicine and consumer culture. This space was articulated through three themes: (i) how "genes" and tests were framed, (ii) how the individual was imagined vis a vis health information, and (iii) the advice and treatments offered. The themes mapped onto four frames or models for genetic testing: (i) clinical genetics, (ii) medicine, (iii) intermediate, and (iv) lifestyle. We suggest that the genomics researchers and policy makers appeared to perform what Gieryn (Gieryn, T.F. (1983). Boundary-work and the demarcation of science from non-science: strains and interests in professional ideologies of scientists. American Sociological Review, 48, 781-795.) has termed "boundary work", i.e., to delegitimize the tests as outside proper medicine and science. Yet, they legitimated them, though in a different way, by defining them as lifestyle, and we contend that the transformation of the boundaries of science into a creation of such hybrid or compromise categories is symptomatic of current historical times. Social scientists studying medicine have referred to the emergence of "lifestyle" products. This article contributes to this literature by examining the historical, regulatory and marketing processes through which certain goods and services become defined this way.

3 July 2017 in New Genetics and Society
Verified
Journal Article
Open access
SHStuart Hogarth
Stuart Hogarth
PSPaula Saukko
Paula Saukko
(2017). A market in the making: the past, present and future of direct-to-consumer genomics. New Genetics and Society: Vol. 36, A Market in the Making: the Past, Present and Future of Direct-To-Consumer Genomics, pp. 197-208.

13 March 2008 in BMJ
Verified
Journal Article
Closed access
PDF file
DMDavid Melzer
David Melzer
SHStuart Hogarth
Stuart Hogarth
KLKatherine Liddell
Katherine Liddell
TLTom Ling
Tom Ling
SSSimon Sanderson
Simon Sanderson
RZRon L Zimmern
Ron L Zimmern
The clinical utility of newly identified genetic variants associated with common diseases needs evaluation Genome-wide studies have recently identified many new variants associated with common diseases. Findings point mainly to sets of variants with modest effects, with many more markers still to be discovered. Some variants are shedding new light on disease mechanisms and on previously unsuspected parts of the genome. Much more work is needed, however, to define the clinical relevance and value to patients of testing for these new genetic markers. It is worrying that in the absence of this knowledge, commercial genetic testing services are being marketed directly to the public. In this paper we describe key findings from the new genome-wide association studies; draw attention to the currently weak regulatory systems, particularly in Europe; and argue the case for improved evaluation, greater transparency, and better regulation, so that the new genetic tests can be used in a safe and informed way. Environmental factors are major contributors to the development of most common diseases. However, conditions including myocardial infarction, type 2 diabetes, asthma, and even the ageing process itself are influenced by inherited variations in DNA sequence.1 The most common DNA variant is the substitution of a single base pair: when these occur at a population prevalence of 1% or more; they are termed single nucleotide polymorphisms or SNPs (pronounced “snips”). More complex variants exist, including deletions, insertions, and copy number variations, but most of the recent work on the genetics of common diseases has focused on SNPs. In tandem with the sequencing of the human genome, extraordinary advances have occurred in the technology for determining the status of SNPs. The original wet laboratory techniques gave way to robotic systems and then to miniaturisation. The latest format has test probes arrayed on the surface of a …